[1] US Global Health Policy. http://www.globalhealthfacts.org
[2] Li, Y., Zhu, Y.-M., Jiang, H.-J., Pan, J.-P., Wu, G.-S., Wu, J.-M., Shi, Y.-L., Yang, Y.-L. and Wu, B.A. (2000) Synthesis and antimalarial activity of artemisinin derivatives containing an amino group. Journal of Medicinal Chemistry, 43, 1635-1640. doi:10.1021/jm990552w
[3] Mekonnen, B., Weiss, E., Katz, E., Ma, J., Ziffer, H. and Kyle, D.E. (2000) Synthesis and antimalarial activities of base-catalyzed adducts of 11-azaartemisinin. Bioorganic & Medicinal Chemistry, 8, 1111-1116. doi:10.1016/S0968-0896(00)00049-3
[4] Winstanley, P.A. (2000) Chemotherapy for falciparum malaria: The armoury, the problems and the prospects. Parasitology Today, 16, 146-153. doi:10.1016/S0169-4758(99)01622-1
[5] Coy, D.F. (2004) Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sciences, 74, 1957-1972. doi:10.1016/j.lfs.2003.10.003
[6] Agarwal, A., Srivastava, K., Puri, S. and Chauhan, P. (2005) Antimalarial activity of 2,4,6-trisubstituted pyri- midines. Bioorganic & Medicinal Chemistry Letters, 15, 1881-1883.
[7] Equbal, T., Silakari, O. and Ravikumar, M. (2008) Exploring three-dimensional quantitative structural activity relationship (3D-QSAR) analysis of SCH 66336 (Sarasar) analogues of farnesyltransferase inhibitors. European Jour- nal of Medicinal Chemistry, 43, 204-209. doi:10.1016/j.ejmech.2007.02.013
[8] Puntambekar, D.S., Giridhar, R. and Yadav, M.R. (2008) Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. European Jour- nal of Medicinal Chemistry, 43, 142-154. doi:10.1016/j.ejmech.2007.02.003
[9] Xie, A., Sivaprakasam, P. and Doerksen, R.J. (2006) 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold. Bioorganic & Medicinal Chemistry, 14, 7311-7323. doi:10.1016/j.bmc.2006.06.041
[10] Xie, A., Odde S. and Prasanna, R.J. (2009) Doerksen, Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking. Journal of Computer-Aided Molecular Design, 23, 431-448. doi:10.1007/s10822-009-9278-z
[11] Srivastava, M., Singh, H. and Naik, P.K. (2009) Quantitative structure-activity relationship (QSAR) of the artemisinin: The development of predictive in vitro antimalarial activity model. Journal of Chemometrics, 23, 618- 635.
[12] Deshpande, S., Solomon, V.R., Katti, S.B. and Prabhakar, Y.S. (2009) Topological descriptors in modelling antimalarial activity: N(1)-(7-chloro-4-quinolyl)-1,4-bis(3-aminopropyl) piperazine as prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 24, 94-104. doi:10.1080/14756360801915377
[13] Freitas, M.P., Brown, S.D. and Martins, J.A. (2005) MIA- QSAR: A simple 2D image-based approach for quantitative structure-activity relationship analysis. Journal of Molecular Structure, 738, 149-154. doi:10.1016/j.molstruc.2004.11.065
[14] Freitas, M.P. (2006) MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Organic & Biomolecular Chemistry, 4, 1154-1159. doi:10.1039/b516396j
[15] Freitas, M.P. (2007) Multivariate QSAR: From classical descriptors to new perspectives. Current Computer-Aided Drug Design, 3, 235-239.
[16] Freitas, M.P. (2008) Multivariate image analysis applied to QSAR: Evaluation to a series of potential anxiolytic agents. Chemometrics and Intelligent Laboratory Systems, 91, 173-176. doi:10.1016/j.chemolab.2007.11.002
[17] Pinheiro, J.R., Bitencourt, M., da Cunha, E.F.F., Ramalho, T.C. and Freitas, M.P. (2008) Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches. Bioorganic & Medicinal Che- mistry, 16, 1683-1690. doi:10.1016/j.bmc.2007.11.020
[18] Goodarzi, M. and Freitas, M.P. (2010) MIA-QSAR modelling of activities of a series of AZT analogues: Bi- and multilinear PLS regression. Molecular Simulation, 36, 267-272. doi:10.1080/08927020903278001
[19] Gupta, M.K. and Prabhakar, Y.S. (2008) QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: A comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity. European Journal of Medicinal Chemistry, 43, 2751-2767. doi:10.1016/j.ejmech.2008.01.025
[20] Puntambekar, D., Giridhar, R. and Yadav, M.R. (2006) 3D-QSAR studies of farnesyl transferase Inhibitors: A comparative molecular field analysis approach. Bioorganic & Medicinal Chemistry Letters, 16, 1821-1827. doi:10.1016/j.bmcl.2006.01.019
[21] Freitas, M.P., da Cunha, E.F.F., Ramalho, T.C. and Goodarzi, M. (2008) Multimode methods applied on MIA descriptors in QSAR. Current Computer-Aided Drug Design, 4, 273-282.
[22] ACD/ChemSketch (2009) Version 12.01, Advanced Che- mistry Development, Inc., Toronto.
[23] Hast, M.A., Fletcher, S., Cummings, C.G., Pusateri, E.E., Blaskovich, M.A., Rivas, K., Gelb, M.H., Van Voorhis, W.C., Sebti, S.M., Hamilton, A.D. and Beese, L.S. (2009) Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology, 16, 181-192. doi:10.1016/j.chembiol.2009.01.014
[24] SpartanPro 1.0.1 Wavefunction, (Irvine, 2001).
[25] Dewar, M.J.S., Zoebisch, E.G., Healy, E.F. and Stewart, J.J.P. (1985) Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. Journal of the American Chemical Society, 107, 3902-3909. doi:10.1021/ja00299a024
[26] Thomsen, R. and Christensen, M.H. (2006) MolDock: A new technique for highaccuracy molecular docking. Jour- nal of Medicinal Chemistry, 49, 3315-3321. doi:10.1021/jm051197e
[27] Golbraikh, A. and Tropsha, A. (2002) Beware of q2! Journal of Molecular Graphics and Modelling, 20, 269-276. doi:10.1016/S1093-3263(01)00123-1
[28] Eastman, R.T., White, J., Hucke, O., Bauer, K., Yokoyama, K., Nallan, L., Chakrabarti, D., Verlinde, C.L., Gelb, M.H., Rathod, P.K. and Van Voorhis, W.C. (2005) Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. Journal of Biological Chemistry, 280, 13554-13559. doi:10.1074/jbc.M413556200
[29] Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25. doi:10.1016/S0169-409X(96)00423-1
[30] Molinspiration Cheminformatics, Bratislava, Slovak Republic. http://www.molinspiration.com
[31] Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shaw, D.E., Shelley, M., Perry, J.K., Francis, P. and Shenkin, P.S.A. (2004) New approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739-1749. doi:10.1021/jm0306430